Sen. Cotton Introduces Bill to Block Drugs From Companies Linked to the Chinese Government
This bill is currently in the early stages of the legislative process after being sent to the Senate Committee on Health, Education, Labor, and Pensions for review. No further actions are scheduled at this time, and the bill is waiting for the committee to decide on its next steps. It is considered active but is not currently moving forward.
This is a partisan bill that would likely face opposition due to fears of rising drug costs and trade retaliation.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Small pharmaceutical companies or distributors that source ingredients or finished products from Chinese-affiliated entities may face disruptions. They could lose access to products they currently sell or need to find new supply sources, which may be more expensive and take time to establish.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
No votes, news coverage, or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Securing America’s Drug Supply from Communist China Act
Analysis generated by AI. Always verify with official sources.